Ascendis Pharma A/S (ASND)

For informational purposes only. Not financial advice.

Ascendis Pharma A/S (ASND) is a publicly traded company trading at $213.15 with a market cap of 12844784979. It holds a high conviction AI score of 75/100 based on fundamental, technical, and sentiment analysis.

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapeutics for unmet medical needs, particularly in endocrinology. Their key product is SKYTROFA, used for treating patients with growth hormone deficiency (GHD).

75/100 AI Score MCap 13B Vol 499K

Company Overview

CEOJan Moller Mikkelsen
Employees1017
HeadquartersHellerup, DK
IPO Year2015

Ascendis Pharma pioneers innovative TransCon technology, transforming peptide therapeutics and addressing unmet medical needs in endocrinology. With SKYTROFA driving growth and a robust pipeline targeting rare diseases, Ascendis offers a compelling investment in next-generation biologics and sustained market leadership.

Investment Thesis

Ascendis Pharma presents a compelling investment opportunity due to its innovative TransCon technology and its successful commercialization of SKYTROFA. The company's strong growth trajectory is fueled by increasing SKYTROFA sales and the potential for further label expansion. The robust pipeline of TransCon-based therapies, targeting significant unmet needs in endocrinology, provides multiple opportunities for future growth and value creation. With a market capitalization of $13.57 billion and a gross margin of 86.8%, Ascendis Pharma demonstrates financial strength and operational efficiency. While the company currently has a negative P/E ratio of -49.22 and a negative profit margin of -36.0%, this is typical for a high-growth biopharmaceutical company investing heavily in R&D and commercialization. The company's beta of 0.43 suggests lower volatility compared to the overall market.

Key Highlights

  • SKYTROFA is approved for pediatric growth hormone deficiency (GHD), addressing a significant unmet medical need.
  • Gross margin of 86.8% demonstrates strong pricing power and efficient manufacturing.
  • Market capitalization of $13.57 billion reflects investor confidence in the company's growth potential.
  • TransCon technology platform enables the development of sustained-release prodrugs with improved efficacy and safety.
  • Robust pipeline of TransCon-based therapies targeting a range of endocrine disorders provides multiple opportunities for future growth.

Competitors

Strengths

  • Innovative TransCon technology platform.
  • Successful commercialization of SKYTROFA.
  • Strong pipeline of TransCon-based therapies.
  • Experienced management team.

Weaknesses

  • Reliance on a single product (SKYTROFA) for revenue.
  • High R&D spending and operating expenses.
  • Negative profitability.
  • Dependence on regulatory approvals for pipeline products.

Catalysts

  • Ongoing: Increasing SKYTROFA sales and market share.
  • Upcoming: Regulatory approval of TransCon PTH for hypoparathyroidism (potential 2027).
  • Upcoming: Regulatory approval of TransCon CNP for achondroplasia (potential 2028).
  • Ongoing: Progress in clinical trials for pipeline products.
  • Ongoing: Expansion into new geographic markets.

Risks

  • Potential: Competition from existing and emerging therapies.
  • Potential: Regulatory setbacks or delays.
  • Ongoing: High R&D spending and operating expenses.
  • Potential: Patent challenges.
  • Ongoing: Reliance on a single product (SKYTROFA) for revenue.

Growth Opportunities

  • Expanding SKYTROFA's Label: Ascendis Pharma has the opportunity to expand SKYTROFA's label to include adult GHD and other indications. The adult GHD market represents a significant growth opportunity, with an estimated market size of several hundred million dollars annually. Securing regulatory approval for adult GHD would significantly increase SKYTROFA's revenue potential and solidify Ascendis Pharma's leadership in the GHD market. This expansion is anticipated within the next 2-3 years.
  • Advancing TransCon PTH: Ascendis Pharma is developing TransCon PTH for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by insufficient parathyroid hormone production. The hypoparathyroidism market is estimated to be worth several billion dollars annually, with a significant unmet need for effective and convenient therapies. TransCon PTH has the potential to become a best-in-class treatment for hypoparathyroidism, offering improved efficacy and safety compared to existing therapies. Phase 3 trials are ongoing, with potential for market launch in 2027.
  • Developing TransCon CNP: Ascendis Pharma is developing TransCon CNP for the treatment of achondroplasia, a genetic disorder that causes dwarfism. The achondroplasia market is estimated to be worth several billion dollars annually, with a growing demand for therapies that address the underlying cause of the disease. TransCon CNP has the potential to improve bone growth and overall health in children with achondroplasia. Clinical trials are underway, with potential for market launch in 2028.
  • Leveraging TransCon Technology: Ascendis Pharma can leverage its proprietary TransCon technology to develop new therapies for a wide range of diseases beyond endocrinology. The TransCon platform enables the creation of sustained-release prodrugs with improved efficacy, safety, and patient convenience. This technology can be applied to various therapeutic areas, including oncology, immunology, and neurology, creating significant growth opportunities for Ascendis Pharma. The company is actively exploring new applications of the TransCon technology.
  • Geographic Expansion: Ascendis Pharma has the opportunity to expand its commercial presence into new geographic markets. While SKYTROFA is currently available in key markets such as the United States and Europe, there are significant opportunities to launch the product in other regions, including Asia and Latin America. Geographic expansion would increase SKYTROFA's revenue potential and further solidify Ascendis Pharma's global leadership in the GHD market. The company is actively evaluating opportunities for geographic expansion.

Opportunities

  • Expanding SKYTROFA's label to include adult GHD.
  • Advancing TransCon PTH for hypoparathyroidism.
  • Developing TransCon CNP for achondroplasia.
  • Leveraging TransCon technology for new therapeutic areas.

Threats

  • Competition from existing and emerging therapies.
  • Regulatory setbacks or delays.
  • Patent challenges.
  • Pricing pressures from payers.

Competitive Advantages

  • Proprietary TransCon technology platform creates a barrier to entry.
  • Strong intellectual property protection for its products and technology.
  • Established commercial infrastructure and distribution network.
  • First-mover advantage in the once-weekly GHD market with SKYTROFA.

About

Ascendis Pharma A/S, founded in 2006 and headquartered in Hellerup, Denmark, is a biopharmaceutical company dedicated to developing innovative therapies that address significant unmet medical needs. The company's core technology, TransCon, enables the creation of sustained-release prodrugs that improve efficacy, safety, and patient convenience. Ascendis Pharma's lead product, SKYTROFA (lonapegsomatropin-tcgd), is a once-weekly human growth hormone therapy approved for pediatric growth hormone deficiency (GHD). This innovative product has quickly gained market share and is a key driver of the company's revenue growth. Beyond SKYTROFA, Ascendis Pharma has a robust pipeline of TransCon-based therapies targeting a range of endocrine disorders, including hypoparathyroidism and achondroplasia. The company's strategic focus is on rare diseases and areas where existing treatments are inadequate. Ascendis Pharma operates globally, with a commercial presence in key markets and a strong network of partners. The company's commitment to innovation and patient-centricity positions it as a leader in the field of endocrinology and a promising player in the broader biopharmaceutical industry.

What They Do

  • Develops and commercializes therapeutics for unmet medical needs.
  • Utilizes TransCon technology to create sustained-release prodrugs.
  • Offers SKYTROFA for treating pediatric growth hormone deficiency (GHD).
  • Develops TransCon hGH for pediatric GHD in Japan.
  • Develops TransCon parathyroid hormone for adult hypoparathyroidism.
  • Develops TransCon CNP for pediatric achondroplasia.
  • Develops TransCon toll like receptors 7/8 agonist for intratumoral delivery.
  • Develops TransCon IL-2 ß/g for systemic delivery.

Business Model

  • Develops proprietary therapeutics using its TransCon technology.
  • Out-licenses or co-develops certain products with partners.
  • Generates revenue through sales of SKYTROFA and future products.
  • Focuses on rare diseases and areas with significant unmet medical needs.

Industry Context

Ascendis Pharma operates within the biotechnology industry, which is characterized by rapid innovation, high R&D spending, and significant regulatory hurdles. The market for growth hormone deficiency (GHD) therapies is estimated to be worth billions of dollars annually, with a growing demand for more convenient and effective treatments. Ascendis Pharma's SKYTROFA competes with existing daily growth hormone injections, offering a less frequent, once-weekly dosing schedule. Competitors include companies like BioMarin Pharmaceutical Inc. (BMRN) and Exelixis, Inc. (EXEL) that are developing therapies for related endocrine disorders. The biotechnology industry is also subject to intense competition and patent challenges.

Key Customers

  • Pediatric patients with growth hormone deficiency (GHD).
  • Adult patients with growth hormone deficiency (GHD).
  • Patients with hypoparathyroidism.
  • Patients with achondroplasia.
AI Confidence: 72% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q4 2025 $245M -$33M $-0.54
Q3 2025 $214M -$61M $-1.00
Q2 2025 $158M -$39M $-0.61
Q1 2025 $101M -$95M $-1.58

Source: Company filings

Chart & Info

Price Chart

Ascendis Pharma A/S (ASND) stock price: $213.15 (-0.14, -0.07%)

Why Bull

  • •Ascendis Pharma's innovative approach to endocrinology, particularly with TransCon technology, is generating excitement. Think of it as a potential game-changer, similar to how CRISPR disrupted gene editing.
  • •Recent insider buying suggests those closest to the company see long-term value. It's like executives loading up on stock before a major product launch.
  • •The community is buzzing about potential label expansions for their key product, hinting at broader market access. This is reminiscent of how a drug like Humira expanded its indications over time.
  • •Positive sentiment is building around the company's pipeline progress, with anticipation for upcoming clinical trial results. It’s the kind of optimism you saw before a major biotech breakthrough.

Why Bear

  • •Competition in the endocrinology space is fierce, with established players holding significant market share. It's a David vs. Goliath situation, similar to smaller biotechs challenging pharma giants.
  • •Community concerns are surfacing regarding the high cost of Ascendis' treatments, potentially limiting patient access. This is a common issue in the pharmaceutical industry, like the pricing debates surrounding new cancer drugs.
  • •There's some skepticism in the market about the long-term efficacy and safety of TransCon technology. It's a reminder that novel technologies can face unforeseen challenges, like gene therapy's early setbacks.
  • •Bearish voices in the community are highlighting potential regulatory hurdles and delays for future product approvals. This is akin to the uncertainty surrounding FDA decisions for new therapies.

Latest News

Technical Analysis

bullish Trend
RSI(14)
65.6
MACD
--
Volume
498,802

Rationale

AI-generated technical analysis for ASND including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Ascendis Pharma A/S (ASND) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for ASND.

Make a Prediction

Set your price target for Ascendis Pharma A/S (ASND), choose a timeframe, and track your prediction accuracy.

Current price: $213.15

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASND.

Price Targets

Low
$250.00
Consensus
$288.82
High
$342.00

Median: $273.00 (+35.5% from current price)

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

75/100

Score Factors

  • Revenue Growth 8/100

    Revenue grew 90.2% YoY, showing strong top-line momentum well above industry average.

  • Gross Margin 10/100

    Gross margin of 86.3% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 6/100

    Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

  • Cash Runway 8/100

    Strong cash reserves of $616M provide a solid financial cushion for growth investments and market downturns.

  • R&D Intensity 10/100

    Investing 41.0% of revenue in R&D signals heavy commitment to innovation and future product pipeline.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 10/100

    Daily turnover of 1.36% indicates healthy liquidity with smooth entry/exit for investors.

  • Price Momentum 6/100

    Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates ASND's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Ascendis Pharma A/S do?

Ascendis Pharma A/S is a biopharmaceutical company that utilizes its innovative TransCon technology to develop and commercialize therapeutics for unmet medical needs, primarily in endocrinology. Their lead product, SKYTROFA, is a once-weekly human growth hormone therapy approved for pediatric growth hormone deficiency (GHD). The company also has a robust pipeline of TransCon-based therapies targeting other endocrine disorders, such as hypoparathyroidism and achondroplasia. Ascendis Pharma's business model focuses on developing proprietary therapeutics, out-licensing or co-developing certain products, and generating revenue through sales of its approved products.

Is ASND stock a good buy?

ASND stock presents a potentially attractive investment opportunity, driven by the successful commercialization of SKYTROFA and a promising pipeline of TransCon-based therapies. While the company currently has negative profitability, this is typical for a high-growth biopharmaceutical company investing heavily in R&D. The company's strong gross margin of 86.8% and innovative technology platform suggest long-term growth potential. However, investors should also consider the risks associated with regulatory approvals, competition, and patent challenges. A balanced approach, considering both the growth potential and the inherent risks, is crucial when evaluating ASND stock.

What are the main risks for ASND?

Ascendis Pharma faces several key risks, including competition from existing and emerging therapies in the GHD market and other therapeutic areas. Regulatory setbacks or delays in the approval of pipeline products could significantly impact the company's growth prospects. Patent challenges to its TransCon technology or its products could also pose a threat. Additionally, the company's reliance on a single product (SKYTROFA) for revenue makes it vulnerable to market fluctuations and competitive pressures. High R&D spending and operating expenses could also strain the company's financial resources.

Is ASND a good stock to buy?

Whether ASND is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Ascendis Pharma A/S's revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.

What is the ASND MoonshotScore?

The MoonshotScore rates ASND from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.

How often is ASND data updated?

ASND prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What do analysts say about ASND?

Analyst coverage for ASND includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.

What are the risks of investing in ASND?

Risk categories for ASND include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on the most recent available information.
  • Future performance is subject to market conditions and regulatory approvals.
  • This analysis is for informational purposes only and should not be considered investment advice.
Data Sources
profilefundamentalsexistingCopy